nach oben

Drugs

Erschienen in:

01.08.2007 | Adis Drug Profile

Bevacizumab in First-Line Treatment of Metastatic Breast Cancer

A Viewpoint by Xavier Pivot

verfasst von: Xavier Pivot

Erschienen in: Drugs | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Excerpt

Vascular endothelial growth factor (VEGF) is crucial for tumour angiogenesis and thus, the inhibition of circulating VEGF by bevacizumab seems a pertinent approach as an anticancer treatment. Whilst the key impact of bevacizumab is associated with vascular regression, the normalisation of tumour vasculature related to treatment with bevacizumab is also of interest. These changes reduce intratumoural pressure, thereby facilitating tumour exposure to chemotherapy. …

Titel: Bevacizumab in First-Line Treatment of Metastatic Breast Cancer
A Viewpoint by Xavier Pivot
verfasst von: Xavier Pivot
Publikationsdatum: 01.08.2007
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 12/2007
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200767120-00011

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2007

Antileukotrienes as Adjunctive Therapy in Acute Asthma

Drospirenone/Ethinylestradiol 3mg/20µg (24/4 Day Regimen)

Bevacizumab

Pharmacotherapy of Mood Disorders and Treatment Discontinuation

Pathophysiology and Management of Diabetic Gastropathy

Rasagiline